Capsiate administration results in an uncoupling protein-3 downregulation, an enhanced muscle oxidative capacity and a decreased abdominal fat content in vivo

Author(s): Faraut B, Giannesini B, Matarazzo V, Le Fur Y, Rougon G, et al


Objectives: The involvement of skeletal muscle mitochondrial uncoupling protein-3 (UCP3) in the control of energy expenditure in skeletal muscle and at the whole-body level is still a matter of debate. We previously reported that UCP3 downregulation is linked to an enhanced mitochondrial energy metabolism in rat skeletal muscle as a result of acute capsiate treatment. Here, we aimed at investigating noninvasively the effects of chronic capsiate ingestion on metabolic changes occurring in exercising gastrocnemius muscle and at the whole-body level.

Methods: We used an original experimental setup allowing a complete noninvasive investigation of gastrocnemius muscle function in situ using 31-phosphorus magnetic resonance spectroscopy. Whole-body fat composition was determined using magnetic resonance imaging and UCP3 gene expression was measured by quantitative real-time RT-PCR analysis.

Results: We found that a 14-day daily administration of capsiate (100 mg kg(-1) body weight) reduced UCP3 gene expression and increased phosphocreatine level at baseline and during the stimulation period in gastrocnemius muscle. During muscle stimulation, pH(i) showed a larger alkalosis in the capsiate group suggesting a lower glycolysis and a compensatory higher aerobic contribution to ATP production. Although the capsiate-treated rats were hyperphagic as compared to control animals, they showed a lower weight gain coupled to a decreased abdominal fat content.

Conclusion: Overall, our data indicated that capsiate administration contributes to the enhancement of aerobic ATP production and the reduction of body fat content coupled to a UCP3 gene downregulation.

Similar Articles

Mitochondrial dysfunction in obesity

Author(s): Bournat JC, Brown CW

Increased oxidative stress in obesity and its impact on metabolic syndrome

Author(s): Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, et al.

Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress

Author(s): Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM

Lipoic acid reduces glycemia and increases muscle GLUT4 content in streptozotocin-diabetic rats

Author(s): Khamaisi M, Potashnik R, Tirosh A, Demshchak E, Rudich A, et al.

Lipoic acid prevents body weight gain induced by a high fat diet in rats: effects on intestinal sugar transport

Author(s): Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Barber A, Martínez JA, et al.

Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice

Author(s): Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, et al.

Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes

Author(s): Soares AF, Guichardant M, Cozzone D, Bernoud-Hubac N, Bouzaïdi-Tiali N

Hypothalamic CB1 Cannabinoid Receptors Regulate Energy Balance in Mice

Author(s): Cardinal P, Bellocchio L, Clark S, Cannich A, Klugmann M, et al.

Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways

Author(s): Zhou L, Sutton GM, Rochford JJ, Semple RK, Lam DD, et al.

A mouse model for the metabolic effects of the human fat mass and obesity associated FTO gene

Author(s): Church C, Lee S, Bagg EA, McTaggart JS, Deacon R, et al.

Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes

Author(s): Kelley DE, He J, Menshikova EV, Ritov VB

Oxidative capacity and aging in human muscle

Author(s): Conley KE, Jubrias SA, Esselman PC

Mitochondrial function and apoptotic susceptibility in aging skeletal muscle

Author(s): Chabi B, Ljubicic V, Menzies KJ, Huang JH, Saleem A, et al.

Excessive loss of skeletal muscle mass in older adults with type 2 diabetes

Author(s): Park SW, Goodpaster BH, Lee JS, Kuller LH, Boudreau R, et al.